Cogent Biosciences price target raised to $13 from $11 at Citi

Citi raised the firm’s price target on Cogent Biosciences (COGT)to $13 from $11 and keeps a Buy rating on the shares. The analyst says Cogent reviewed positive bezuclastinib data for non-advanced systematic mastocytosis on Friday. Despite the caveats of cross-trial comparisons, Citi’s side-by-side of bezuclastinib and Blueprint’s (BPMC) Ayvakit and elenestinib suggests that the 100mg dose could confer competitive efficacy in a pivotal trial, the analyst tells investors in a research note.